RecruitingPhase 1Phase 2NCT07760454

A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

A Phase I/II Clinical Trial to Evaluate the Safety, Efficacy, and Cellular Kinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma

Sponsor

UCARsgen Biotech Limited

Enrollment

68 participants

Start Date

Sep 3, 2026

Study Type

INTERVENTIONAL

Conditions

Relapsed/Refractory Multiple Myeloma

Summary

This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM). The study aims to evaluate the safety, tolerability, efficacy, cellular kinetics, and immunogenicity of CT0596.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CT0596 for people with relapsed/refractory multiple myeloma. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.